- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02743312
Long-Term Effects of Torso-Weighting (TWPS)
Long-Term Effects of Balance-Based Torso-Weighting: Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Oakland, California, United States, 94609
- Samuel Merritt University, Motion Analysis Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Self-reported a diagnosis of multiple sclerosis
- Self-reported mild or moderate gait or balance difficulties
- Living in the community rather than in a care facility
- Able to walk independently for at least one minute at a time with or without an assistive device
- No exacerbations within the past 2 months
- Able to get to the testing area and tolerate 2-3 hours of testing for each assessment occasion
- Willing to be nudged by a researcher when standing
Exclusion Criteria:
- Unable to comprehend and follow instructions in English
- Current diagnosis of other neurological disorders such as head injury, stroke, Parkinson disease, or other conditions that affect gait or balance (self-reported)
- Experiencing pain that could be exacerbated by external perturbation while standing
- History of skin reaction to adhesives
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Torso Weights then Sham Weights
No weights worn for 4 weeks. Garment with torso weights worn 2-4 hours daily for 2 weeks. Then participants cross-over to wear garment with sham weights for 2-4 hours daily for 2 weeks. Participants wear the Fitbit Flex throughout. |
Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss.
Other Names:
Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss.
The garment is then taken by another investigator and the actual weights are replaced with sham weights.
Other Names:
Potential effect on participants' physical activity to see their own step count using this wrist-worn remote monitoring device.
Other Names:
|
Experimental: Sham Weights then Torso Weights
No weights worn for 4 weeks. Garment with sham weights worn 2-4 hours daily for 2 weeks. Then participants cross-over to wear garment with torso weights for 2-4 hours daily for 2 weeks. Participants wear the Fitbit Flex throughout. |
Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss.
Other Names:
Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss.
The garment is then taken by another investigator and the actual weights are replaced with sham weights.
Other Names:
Potential effect on participants' physical activity to see their own step count using this wrist-worn remote monitoring device.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Steps Per Day
Time Frame: up to 8 weeks
|
Continuous activity data collection via commercially-available remote monitoring device and stored on server.
|
up to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensory Organization Test
Time Frame: change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
balance tested during 6 conditions on Neuro-com forceplate and surround and reported as a composite score (across the six conditions), 0-100, with higher scores indicating better balance; measure reported reflects change in the composite score from the visit that initiates Torso-weighting (TW) or sham weights (SW) to the visit that concludes daily wearing of TW or SW
|
change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
Gait Velocity
Time Frame: change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
As measured using instrumented gait mat.
|
change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
Movement Ability Measure, Computer Adaptive Test Version (MAM-CAT)
Time Frame: change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
Online self-report of perceived current movement ability and preferred movement ability.
The scores are reported in standardized logits, 0-6, where 6 is competitive level athletic movement.
The reported values are the average change in current movement ability from initiation of daily wear to after 2 weeks of daily wear of TW or SW.
|
change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
Activities-Specific Balance Confidence Scale
Time Frame: change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
Self-report measure of perception of confidence under various balance challenges on a scale of 0-100 with 100 being fully confident that the individual can perform the listed balance challenge without falling.
Data reported reflect the difference in scores from initiation to the 2-week point after initiation of TW or SW.
|
change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
Multiple Sclerosis Impact Scale 29
Time Frame: change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
Self-report measure of the impact of MS on activities and participation.
The scale is reported in a physical and psychological subscale, with higher numbers (out of 100) indicating worse impact of multiple sclerosis (MS) on function.
Data are reported as change from initiation of TW or SW to end of 2 weeks of daily wear.
|
change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
Multiple Sclerosis Walking Scale 12
Time Frame: change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
Self-report measure of the effect of MS on walking ability.
Larger numbers out of 100 mean that MS limits walking much more.
Data are reported as change in score from initiation of TW or SW to the visit after 2 weeks of daily wear of TW or SW.
|
change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
Six-Minute Walk Test
Time Frame: change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
distance participant walks in 6 minutes.
Larger numbers indicate more distance covered.
Data reported are the change in distance walked from initiation of TW or SW to after 2 weeks of daily wear.
|
change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
Stride Length
Time Frame: change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
As measured using instrumented gait mat.
|
change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
Percent of Gait Cycle in Single Limb Support
Time Frame: change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
As measured in percent (e.g., 0.35) of gait cycle spent on one limb using instrumented gait mat.
|
change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
Step Width
Time Frame: change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
As measured using instrumented gait mat.
|
change from initiation to 2-weeks after initiation of daily wearing of TW or SW
|
Electromyography to Assess Muscle Activation
Time Frame: Week 4, Week 6, Week 8
|
Recording of muscle activation during quiet and perturbed standing before and after intervention at weeks 4, 6, and 8. Average values with and without weighting during each visit.
|
Week 4, Week 6, Week 8
|
Number of Falls Recorded in 2 Weeks of Wear Time.
Time Frame: count of number of falls recorded at the end of two weeks of wearing TW or SW
|
Daily log manually recorded by participant for the 2 weeks of wear time.
This is a descriptive measure recording the total count (number) of falls per arm.
|
count of number of falls recorded at the end of two weeks of wearing TW or SW
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Diane Allen, PhD, San Francisco State University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- X15-48a
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Torso Weights
-
Vastra Gotaland RegionGöteborg UniversityCompleted
-
Neuro Counsel Hospital, PakistanCompleted
-
Vastra Gotaland RegionGöteborg UniversityCompleted
-
University of Alabama at BirminghamChildren's Health System, AlabamaWithdrawn
-
Maxine MendelsonUnknown
-
University of Alabama at BirminghamChildren's Health System, AlabamaCompletedHypothermia | NewbornZambia
-
University of Alabama at BirminghamChildren's Health System, AlabamaActive, not recruitingHypothermia | Immature NewbornZambia
-
Children's Hospital of PhiladelphiaLaerdal MedicalCompletedCardiac Arrest | Cardiac Output | Central Venous Pressure | CPR | Perfusion PressuresUnited States
-
Beni-Suef UniversityNot yet recruiting
-
Sarah KeimOhio State University; American Diabetes Association; Ohio Department of HealthCompleted